The antiapoptotic protein myeloid cell leukemia1 (Mcl-1), which is associated with high tumor grade, poor survival,and resistance to treatment, has emerged as a promising candidatefor treating hematological and solid cancers. This evidence concerns the gene MCL1 and neoplasm.